{"nctId":"NCT01499082","briefTitle":"Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin","startDateStruct":{"date":"2011-12"},"conditions":["Type 2 Diabetes Mellitus"],"count":807,"armGroups":[{"label":"HOE901-U300","type":"EXPERIMENTAL","interventionNames":["Drug: HOE901-U300 (new formulation of insulin glargine)"]},{"label":"Lantus","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Lantus (insulin glargine)"]}],"interventions":[{"name":"HOE901-U300 (new formulation of insulin glargine)","otherNames":[]},{"name":"Lantus (insulin glargine)","otherNames":["Lantus"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria :\n\n* Participants with type 2 diabetes mellitus\n* Substudy inclusion criteria:\n\n  * Completion of the 6-month study period in main study (Visit 10)\n  * Randomized and treated with insulin glargine new formulation during the 6-month treatment period (Baseline - month 6)\n\nExclusion criteria:\n\n* Age less than (\\<) 18 years\n* HbA1c \\<7.0% or greater than (\\>) 10% at screening\n* Diabetes other than type 2 diabetes mellitus\n* Less than 1 year on basal plus mealtime insulin and self-monitoring of blood glucose\n* Any contraindication to use of insulin glargine as defined in the national product label\n* Participants using human regular insulin as mealtime insulin in the last 3 months before screening visit\n* Use of an insulin pump in the last 6 months before screening visit\n* Initiation of new glucose-lowering agents and/or weight loss drugs in the last 3 months before screening visit\n* History or presence of significant diabetic retinopathy or macular edema likely to require laser or injectable drugs or surgical treatment during the study period\n* Pregnant or breast-feeding women or women who intend to become pregnant during the study period\n* Substudy exclusion criteria:\n\n  * Participant not willing to use the adaptable injection intervals on at least two days per week\n\nThe above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in HbA1c From Baseline to Month 6 Endpoint","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.83","spread":"0.060"},{"groupId":"OG001","value":"-0.83","spread":"0.061"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With At Least One Severe and/or Confirmed Nocturnal Hypoglycemia From Start of Week 9 to Month 6 Endpoint","description":"Nocturnal hypoglycemia was hypoglycemia that occurred between 00:00 and 05:59 hours (clock time), regardless the participant was awake or woke up because of the event. Severe hypoglycemia was an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Confirmed hypoglycemia was an event associated with plasma glucose less than or equal to (\\<=) 3.9 millimoles per liter (mmol/L) (70 milligram per deciliter \\[mg/dL\\]).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.1","spread":null},{"groupId":"OG001","value":"46.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Average Preinjection Self-Monitored Plasma Glucose (SMPG) From Baseline to Month 6 Endpoint","description":"Pre-injection SMPG was measured within 30 minutes prior to the injection of the study drug. Average was assessed by the mean of at least 3 SMPG calculated over the 7 days preceding the assessment visit.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.90","spread":"0.182"},{"groupId":"OG001","value":"-0.84","spread":"0.182"}]}]}]},{"type":"SECONDARY","title":"Change in Variability of Preinjection SMPG From Baseline to Month 6 Endpoint","description":"Pre-injection SMPG was measured within 30 minutes prior to the injection of the study drug. Variability was assessed by the mean of coefficient of variation calculated as 100 multiplied by (standard deviation/mean) over at least 3 SMPG measured during the 7 days preceding the assessment visit.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.10","spread":"1.222"},{"groupId":"OG001","value":"-1.08","spread":"1.222"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HbA1c <7% at Month 6 Endpoint","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.6","spread":null},{"groupId":"OG001","value":"40.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose (FPG) From Baseline to Month 6 Endpoint","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.29","spread":"0.191"},{"groupId":"OG001","value":"-1.38","spread":"0.192"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With FPG <5.6 mmol/L (<100 mg/dL) at Month 6 Endpoint","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.5","spread":null},{"groupId":"OG001","value":"23.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in 8-Point SMPG Profiles Per Time Point From Baseline to Month 6 Endpoint","description":"Change in each time-point of 8-point SMPG profile: 03:00 hours (clock time) at night; before and 2 hours after breakfast; before and 2 hours after lunch; before and 2 hours after dinner; and at bedtime.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.98","spread":"0.248"},{"groupId":"OG001","value":"-1.16","spread":"0.251"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.19","spread":"0.189"},{"groupId":"OG001","value":"-1.49","spread":"0.190"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.60","spread":"0.241"},{"groupId":"OG001","value":"-1.90","spread":"0.243"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.05","spread":"0.213"},{"groupId":"OG001","value":"-1.23","spread":"0.216"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.64","spread":"0.280"},{"groupId":"OG001","value":"-0.63","spread":"0.282"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.47","spread":"0.261"},{"groupId":"OG001","value":"-0.37","spread":"0.260"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.96","spread":"0.298"},{"groupId":"OG001","value":"-1.17","spread":"0.298"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.88","spread":"0.324"},{"groupId":"OG001","value":"-0.91","spread":"0.326"}]}]}]},{"type":"SECONDARY","title":"Change in Daily Basal Insulin Dose From Baseline to Month 6 Endpoint","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.28","spread":"0.017"},{"groupId":"OG001","value":"0.19","spread":"0.017"}]}]}]},{"type":"SECONDARY","title":"Change in Treatment Satisfaction Score Using The Diabetes Treatment Satisfaction Questionnaire (DTSQs) From Baseline to Month 6 Endpoint","description":"DTSQ is a validated measure to assess how satisfied participants with diabetes are with their treatment and how they perceive hyper- and hypoglycemia. It consists of 8 questions which are answered on a Likert scale from 0 to 6. DTSQ treatment satisfaction score is the sum of question 1 and 4-8 scores and ranges between 0 and 36, where higher scores indicate more treatment satisfaction.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.32","spread":"0.310"},{"groupId":"OG001","value":"2.24","spread":"0.313"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Hypoglycemia (All and Nocturnal) Events From Baseline up to Month 12","description":"Hypoglycemia events were Severe hypoglycemia (an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions); Documented symptomatic hypoglycemia (typical symptoms of hypoglycemia with plasma glucose level of \\<=3.9 mmol/L \\[70 mg/dL\\]); Asymptomatic hypoglycemia (no typical symptoms of hypoglycemia but plasma glucose level \\<=3.9 mmol/L); Probable symptomatic hypoglycemia (an event during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination, but was presumably caused by a plasma glucose level \\<=3.9 mmol/L, symptoms treated with oral carbohydrate without a test of plasma glucose); Relative hypoglycemia (an event during which the person with diabetes reported any of the typical symptoms of hypoglycemia, and interpreted the symptoms as indicative of hypoglycemia, but plasma glucose level \\>3.9 mmol/L); Severe and/or confirmed a hypoglycemia (plasma glucose \\<=3.9 mmol/L).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.4","spread":null},{"groupId":"OG001","value":"92.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":null},{"groupId":"OG001","value":"7.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.8","spread":null},{"groupId":"OG001","value":"82.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.5","spread":null},{"groupId":"OG001","value":"73.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","spread":null},{"groupId":"OG001","value":"8.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.8","spread":null},{"groupId":"OG001","value":"21.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.9","spread":null},{"groupId":"OG001","value":"91.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.4","spread":null},{"groupId":"OG001","value":"66.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":null},{"groupId":"OG001","value":"3.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.6","spread":null},{"groupId":"OG001","value":"57.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.2","spread":null},{"groupId":"OG001","value":"31.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":null},{"groupId":"OG001","value":"2.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":null},{"groupId":"OG001","value":"10.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.5","spread":null},{"groupId":"OG001","value":"64.7","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change in HbA1c From Month 6 to Month 9","description":"Substudy comparing fixed dosing regimen (every 24 hours) vs. adaptive dosing regimen (every 24 +/- 3 hours) in a subset of participants randomized to HOE901-U300 and treated for 6 months.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.21","spread":"0.111"},{"groupId":"OG001","value":"0.15","spread":"0.120"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":53,"n":404},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Bronchitis","Diarrhoea","Influenza"]}}}